The U.S. Food and Drug Administration has expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. Thyroid cancer is a cancerous growth of the thyroid gland, which is located in the neck. Differentiated thyroid cancer is the most common type of thyroid cancer. The National Cancer Institute estimates that 60,220 Americans will be diagnosed with thyroid cancer and 1,850 will die from the disease in 2013. Nexavar works by inhibiting multiple proteins in cancer cells, limiting cancer cell growth and division.
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment